Skip to content

Continuous test for thin hair male of hair tonic "Finjia" preparations containing Capixyl and Kopyrrol.

Continuous test for thin hair male of hair tonic "Finjia" preparations containing Capixyl and Kopyrrol. - YP-1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027755
Enrollment
10
Registered
2017-06-18
Start date
2017-07-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thinning hair

Interventions

Subjects apply &quot
Finjia&quot
one to two times per day on the scalp and continue it for 24 weeks.

Sponsors

Nihon Pharmaceutical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Japanese man 39 years or younger 20 years old or older. 2.Those who are concerned about thin hair as of the date of consent. 3.Subject with understanding of this study and obtained informed consent.

Exclusion criteria

Exclusion criteria: 1. Person who dyes white hair 2. Persons conducting hair transplantation and wearing wigs 3. Persons who are likely to have allergic symptoms with test substance components 4. Persons who may show skin allergy symptoms and people with skin hypersensitivity 5. Persons who have experienced serious heart disease, renal disease, liver disease, cancer in the past 6. Currently those who are treating hypertension 7. Persons who routinely use health foods, cosmetics, quasi-drugs, medicines that are likely to affect the results of the examination 8. Other persons who judged that it is inappropriate for the doctor in charge or the person in charge of the examination to incorporate in the exam

Design outcomes

Primary

MeasureTime frame
Phototrichogram. Evaluation period : pre-administar Finjia, 12 week after, 24 week after

Countries

Japan

Contacts

Public ContactHiromu Katsuta

Lelife Co., Ltd Clinical personnel development Division

hkatsuta@relife-inc.com03-5928-2501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026